Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.04
-0.01 (-0.10%)
Apr 23, 2025, 4:00 PM EDT - Market closed
| Market Cap | 336.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -479,734 |
| Shares Out | 33.52M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 225 |
| Open | 10.04 |
| Previous Close | 10.05 |
| Day's Range | 10.04 - 10.04 |
| 52-Week Range | 9.95 - 10.27 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About DMAA
Drugs Made In America Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses in the pharmaceutical industry. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida. [Read more]
Industry Shell Companies
Sector Financials
IPO Date Jan 28, 2025
Country United States
Stock Exchange NASDAQ
Ticker Symbol DMAA
Website https://dmaacorp.com
News
SPAC Drugs Made In America Acquisition files for a $500 million IPO
Drugs Made In America Acquisition, a blank check company targeting pharmaceutical businesses in the US, filed on Thursday with the SEC to raise up to $500 million in an initial public offering.
9 months ago - Renaissance Capital
Drugs Made In America Acquisition IPO Registration Document (S-1)
Drugs Made In America Acquisition has filed to go public with an IPO on the NASDAQ.
9 months ago - SEC